Cargando…
Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells
Inactivating mutations in ARID1A are found in a broad spectrum of cancer types, with the highest frequency in gynecologic cancers. However, therapeutic strategies targeting ARID1A-mutant cancer cells remain limited. In this study, we aimed to identify drugs sensitivities in ARID1A-mutant cancer cell...
Autores principales: | Kwan, Suet-Yan, Cheng, Xuanjin, Tsang, Yvonne T.M., Choi, Jong-Sun, Kwan, Suet-Ying, Izaguirre, Daisy I., Kwan, Hoi-Shan, Gershenson, David M., Wong, Kwong-Kwok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302963/ https://www.ncbi.nlm.nih.gov/pubmed/27486766 http://dx.doi.org/10.18632/oncotarget.10921 |
Ejemplares similares
-
The Role of GDF15 in Regulating the Canonical Pathways of the Tumor Microenvironment in Wild-Type p53 Ovarian Tumor and Its Response to Chemotherapy
por: Izaguirre, Daisy I., et al.
Publicado: (2020) -
PAX2 Expression in Ovarian Cancer
por: Song, Huijuan, et al.
Publicado: (2013) -
Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas
por: Crane, Erin K., et al.
Publicado: (2015) -
Pathogenesis and Clinical Management of Uterine Serous Carcinoma
por: Zhang, Li, et al.
Publicado: (2020) -
Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)